Production of 3-desmethyl protostreptovaricin I from the genetically engineered Streptomyces spectabilis CCTCC M2017417-Reference-Cited by-同舟云学术

Production of 3-desmethyl protostreptovaricin I from the genetically engineered Streptomyces spectabilis CCTCC M2017417

Published:2020-09-18 Issue:10 Volume:23 Page:1015-1021
ISSN:1028-6020
Container-title:Journal of Asian Natural Products Research
language:en
Short-container-title:Journal of Asian Natural Products Research

Author:

Liu Yuanzhen¹²³,Cui Xiqing⁴,Li Zhengyuan³,Chen Xu³,Zeng Guoping¹²,Sun Yuhui³

Affiliation:

1. School of Chemistry and Life Sciences, Hubei University of Education, Wuhan 430205, China

2. Hubei Key Laboratory of Purification and Application of Plant Anti-Cancer Active Ingredients, Hubei University of Education, Wuhan 430205, China

3. Key Laboratory of Combinatorial Biosynthesis and Drug Discovery (Wuhan University), Ministry of Education, and School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China

4. Deqiang Biology Co., Ltd, Harbin 150060, China

Funder

Research Start-up Funding of Hubei University of Education

Natural Science Foundation of Hubei Province, China

Special Funding of Prevention and Cure of COVID-19, Hubei University of Education

Publisher

Informa UK Limited

Subject

Organic Chemistry,Complementary and alternative medicine,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,General Medicine,Analytical Chemistry

Link

https://www.tandfonline.com/doi/pdf/10.1080/10286020.2020.1816976

Reference11 articles.

1. Biosynthesis of 3,5-AHBA-derived natural products

2. Rifamycins – Obstacles and opportunities

3. RifamycinMode of Action, Resistance, and Biosynthesis

4. Rifapentine for the Treatment of Pulmonary Tuberculosis

5. Rifaximin pharmacology and clinical implications